Cardiovascular Outcomes Reported in Hemodialysis Trials.
暂无分享,去创建一个
M. Rocco | A. Webster | A. Levin | M. Tonelli | C. Wanner | F. Zannad | M. Jardine | J. Craig | D. Wheeler | W. Winkelmayer | A. Tong | T. Jafar | C. Herzog | A. Wang | G. Strippoli | E. O'Lone | J. Małyszko | W. Herrington | D. Roy | V. Krane | B. Sautenet | A. Viecelli | A. Wang | A. Levin
[1] P. Tugwell,et al. Core Outcome Set–STAndards for Reporting: The COS-STAR Statement , 2016, PLoS medicine.
[2] David W. Johnson,et al. Patient and Caregiver Priorities for Outcomes in Hemodialysis: An International Nominal Group Technique Study. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[3] D. Altman,et al. Improving the relevance and consistency of outcomes in comparative effectiveness research. , 2016, Journal of comparative effectiveness research.
[4] Connie M. Rhee,et al. US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[5] R. Autschbach,et al. A core outcome set for all types of cardiac surgery effectiveness trials: a study protocol for an international eDelphi survey to achieve consensus on what to measure and the subsequent selection of measurement instruments , 2015, Trials.
[6] David W. Johnson,et al. Standardised outcomes in nephrology – Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis , 2015, Trials.
[7] Eric E. Smith,et al. 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). , 2015, Circulation.
[8] G. Perkins,et al. A systematic review of the outcomes reported in cardiac arrest clinical trials: the need for a core outcome set. , 2015, Resuscitation.
[9] C. Terwee,et al. Core Outcome Measures in Effectiveness Trials (COMET) initiative: protocol for an international Delphi study to achieve consensus on how to select outcome measurement instruments for outcomes included in a ‘core outcome set’ , 2014, Trials.
[10] Harlan M Krumholz,et al. Increasing value and reducing waste: addressing inaccessible research , 2014, The Lancet.
[11] R. Tibshirani,et al. Increasing value and reducing waste in research design, conduct, and analysis , 2014, The Lancet.
[12] A. Martínez‐Castelao,et al. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. , 2013, Journal of the American Society of Nephrology : JASN.
[13] Nick Black,et al. Patient reported outcome measures could help transform healthcare , 2013, BMJ.
[14] K. Mahaffey,et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. , 2012, The New England journal of medicine.
[15] Jane M Blazeby,et al. Developing core outcome sets for clinical trials: issues to consider , 2012, Trials.
[16] P. Williamson,et al. Development of a core outcome set for clinical trials in childhood asthma: a survey of clinicians, parents, and young people , 2012, Trials.
[17] M. Bots,et al. Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. , 2012, Journal of the American Society of Nephrology : JASN.
[18] V. Montori,et al. The idolatry of the surrogate , 2011, BMJ : British Medical Journal.
[19] G. Remuzzi,et al. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. , 2011, Kidney international.
[20] Paul Heidenreich,et al. ACCF/AHA 2011 Key Data Elements and Definitions of a Base Cardiovascular Vocabulary for Electronic Health Records: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards , 2011, Circulation.
[21] R. Hendel,et al. ACCF/AHA 2011 key data elements and definitions of a base cardiovascular vocabulary for electronic health records: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards. , 2011, Journal of the American College of Cardiology.
[22] M. Landray,et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.
[23] Nicholas C. Ide,et al. The ClinicalTrials.gov results database--update and key issues. , 2011, The New England journal of medicine.
[24] U. Patel. Faculty Opinions recommendation of In-center hemodialysis six times per week versus three times per week. , 2010 .
[25] G. Beck,et al. In-center hemodialysis six times per week versus three times per week. , 2010, The New England journal of medicine.
[26] H. Kölsch,et al. Reporting bias in medical research - a narrative review , 2010, Trials.
[27] Gert Mayer,et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. , 2009, The New England journal of medicine.
[28] Kevin E. Kip,et al. The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. , 2008, Journal of the American College of Cardiology.
[29] P. Tugwell,et al. OMERACT: An international initiative to improve outcome measurement in rheumatology , 2007, Trials.
[30] G. Guyatt,et al. Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns. , 2007, Journal of clinical epidemiology.
[31] Gordon H Guyatt,et al. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials , 2007, BMJ : British Medical Journal.
[32] W. März,et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.
[33] J. Aronson. Biomarkers and surrogate endpoints. , 2005, British journal of clinical pharmacology.
[34] M. Rocco,et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. , 2004, Kidney international.
[35] R. Foley,et al. Epidemiology of cardiovascular disease in chronic renal disease , 2000 .
[36] R. Petersen,et al. Clinical Subtypes of Alzheimer’s Disease , 1998, Dementia and Geriatric Cognitive Disorders.
[37] P. Serruys,et al. Usefulness of quantitative and qualitative angiographic lesion morphology, and clinical characteristics in predicting major adverse cardiac events during and after native coronary balloon angioplasty. CARPORT and MERCATOR Study Groups. , 1993, The American journal of cardiology.
[38] Theresa Schilhab,et al. Issues to Consider , 2017 .
[39] Eric E. Smith,et al. 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). , 2015, Journal of the American College of Cardiology.
[40] Hugh Calkins,et al. ACC/AHA/HRS 2006 key data elements and definitions for electrophysiological studies and procedures: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (ACC/AHA/HRS Writing Committee to Develop Data Standards on Electrophysiology). , 2006, Circulation.
[41] David C. Murray,et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. , 1995, Kidney international.